3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Thoracic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Melanoma
7
Carcinoma, Renal Cell
3
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Neuroblastoma
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
27
Nivolumab
20
atezolizumab
6
Ipilimumab
6
Magnetic Resonance Spectroscopy
5
Specimen Handling
4
Paclitaxel
4
Docetaxel
4
Cyclophosphamide
4
Carboplatin
4
fludarabine
3
avelumab
3
Pemetrexed
3
Interleukin-2
3
tislelizumab
2
epacadostat
2
durvalumab
2
aldesleukin
2
Taxes
2
Radiosurgery
2
Cisplatin
2
veliparib
1
toripalimab
1
spartalizumab
1
sotigalimab
1
sonidegib
1
sargramostim
1
regorafenib
1
poly ICLC
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
bempegaldesleukin
×
Dermatologic
×
Clear all
NCT02983045
2023-03-13
PIVOT-02
Nektar Therapeutics
Phase 1/2
Completed
557 enrolled
22 charts